<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03411876</url>
  </required_header>
  <id_info>
    <org_study_id>IPF Oxymizer study II</org_study_id>
    <nct_id>NCT03411876</nct_id>
  </id_info>
  <brief_title>Effects of Oxymizer Pendant Cannula Versus Conventional Nasal Cannula During Endurance Shuttle Walk Tests in Hypoxemic Patients With Idiopathic Pulmonary Fibrosis</brief_title>
  <acronym>IPF/Oxymizer2</acronym>
  <official_title>Effects of an Oxymizer Pendant Cannula Versus a Conventional Nasal Cannula During Endurance Shuttle Walk Test (ESWT) in Hypoxemic Patients With Idiopathic Pulmonary Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Klaus Kenn</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Schön Klinik Berchtesgadener Land</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Schön Klinik Berchtesgadener Land</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of this study is to investigate the effects of an Oxymizer pendant nasal cannula in
      hypoxemic patients with idiopathic pulmonary fibrosis during walking.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be recruited during an inpatient pulmonary rehabilitation program. They will
      perform three shuttle walk tests on three consecutive days (see below). While performing
      those tests, the patient's prescribed oxygen flow rate is applicated either through the
      conventional nasal cannula (CNC) or the Oxymizer.On the first day, patients perform an
      incremental shuttle walk test to determine maximum walking speed using a conventional nasal
      cannula.

      On two consecutive days, patients will perform two endurance shuttle walk tests at 85% of the
      maximum incremental shuttle walk test speed. Supplemental oxygen will be provided via nasal
      cannula at the prescribed oxygen flow rate. Patients will be randomly assigned to perform one
      test with the Oxymizer and the other one with a conventional nasal cannula.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 18, 2018</start_date>
  <completion_date type="Actual">January 15, 2019</completion_date>
  <primary_completion_date type="Actual">January 15, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endurance shuttle walk test distance</measure>
    <time_frame>at baseline, at isotime of endurance shuttle walk test and at the end (maximum 20 min) of endurance shuttle walk test</time_frame>
    <description>Distance patients walk during an endurance shuttle walk test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>oxygen saturation</measure>
    <time_frame>at baseline, at isotime of endurance shuttle walk test and at the end (maximum 20 min) of endurance shuttle walk test</time_frame>
    <description>measured by Sentec Digital Monitoring System</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>heart rate</measure>
    <time_frame>at baseline, at isotime of endurance shuttle walk test and at the end (maximum 20 min) of endurance shuttle walk test</time_frame>
    <description>measured by Sentec Digital Monitoring System</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>breathing frequency</measure>
    <time_frame>at baseline, at isotime of endurance shuttle walk test and at the end (maximal 20 min) of endurance shuttle walk test</time_frame>
    <description>measured by NoxT3 device</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>carbon dioxide pressure</measure>
    <time_frame>at baseline, at isotime of endurance shuttle walk test and at the end (maximum 20 min) of endurance shuttle walk test</time_frame>
    <description>transcutaneously carbon dioxide pressure measured by Sentec Digital Monitoring System</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to desaturation</measure>
    <time_frame>From beginning of endurance shuttle walk test until the oxygen saturation reaches defined thresholds, or ESWT reaches maximum time frame of 20 minutes</time_frame>
    <description>time (seconds) is measured until oxygen saturation drops below 90% or 85 % respectively</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <condition>Hypoxemia</condition>
  <arm_group>
    <arm_group_label>First ESWT with Oxymizer, second ESWT with CNC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this study arm first perform the first endurance shuttle walk test (ESWT) with the Oxymizer and the second ESWT with a conventional nasal cannula (CNC).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>First ESWT with CNC, second ESWT with Oxymizer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this study arm first perform the first endurance shuttle walk test (ESWT) with the CNC and the second ESWT with the Oxymizer.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Oxymizer® pendant nasal cannula</intervention_name>
    <description>Supplemental oxygen is provided by an Oxymizer pendant nasal cannula.</description>
    <arm_group_label>First ESWT with CNC, second ESWT with Oxymizer</arm_group_label>
    <arm_group_label>First ESWT with Oxymizer, second ESWT with CNC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>conventional nasal cannula</intervention_name>
    <description>Supplemental oxygen is provided by a conventional nasal cannula.</description>
    <arm_group_label>First ESWT with CNC, second ESWT with Oxymizer</arm_group_label>
    <arm_group_label>First ESWT with Oxymizer, second ESWT with CNC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  firmed diagnosis of idiopathic pulmonary fibrosis

          -  indication for supplemental oxygen therapy during exercise

          -  referred to an inpatient rehabilitation program at the Schön Klinik Berchtesgadener
             Land

        Exclusion Criteria:

          -  cardiovascular diseases that influence the patient's physical performance

          -  orthopedic comorbidities that prevent the patient from performing an incremental or
             endurance shuttle walk test

          -  carbon dioxide pressure above 45 mmHg at rest and ambient air
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Schön Klinik Berchtesgadener Land</name>
      <address>
        <city>Schönau Am Königssee</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>January 18, 2018</study_first_submitted>
  <study_first_submitted_qc>January 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 26, 2018</study_first_posted>
  <last_update_submitted>April 15, 2020</last_update_submitted>
  <last_update_submitted_qc>April 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Schön Klinik Berchtesgadener Land</investigator_affiliation>
    <investigator_full_name>Klaus Kenn</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <keyword>IPF</keyword>
  <keyword>Oxymizer</keyword>
  <keyword>oxygen conserving device</keyword>
  <keyword>pulmonary disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

